journal article·2021-08

Sub‐50 nm Supramolecular Nanohybrids with Active Targeting Corona for Image‐Guided Solid Tumor Treatment and Metastasis Inhibition

Yunkun Li, Dan Zhong, Chuan Zhou, Zhaoxu Tu, Hongli Mao, Jun Yang, Hu Zhang, Kui Luo, Qiyong Gong, Zhongwei Gu

Advanced Functional Materials· Volume 31· Issue 34
Publisher page

Abstract

Abstract Tumor metastasis is responsible for almost 90% of failure in cancer therapy and it is also the major cause of cancer‐associated mortality due to poor vascularization. Herein, a sub‐50 nm hybrid theranostic robust nanoplatform is developed via a template supramolecular strategy to achieve active targeting and deep penetration of primary tumors as well as metastatic tumors with poor vascular structures. Quantum dots (QDs) as a template are coordinated with lipoic acid (LA)‐functionalized dendrimers for covalent loading of doxorubicin (DOX) and Arg‐Gly‐Asp (RGD) tripeptide‐functionalized polyethylene glycol (PEG) for prolonging blood circulation and selectively targeting cancer cells. When the nanohybrid is internalized into tumor cells, DOX releases from the nanohybrid in acidic lysosomes and is translocated into nuclei for arresting cell cycles at the G2/M phase, leading to a remarkably therapeutic effect for both primary tumors and distant metastases in a 4T1 xenograft tumor model. The inherent fluorescence of QDs in the nanohybrid allows real‐time monitoring of the therapeutic responses from primary and metastasis tumors. Hence, a facile strategy is demonstrated to construct a hybrid nanoplatform with multifunctionality for inhibition of both primary and metastatic cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanocluster Synthesis and Applications · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Huaxi MR Research Center (HMRRC) Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province National Clinical Research Center for Geriatrics West China Hospital Sichuan University, and National Engineering Research Center for Biomaterials Sichuan University Chengdu 610064 P. R. China

Research Institute for Biomaterials Tech Institute for Advanced Materials College of Materials Science and Engineering NJTech‐BARTY Joint Research Center for Innovative Medical Technology Nanjing Tech University Nanjing 211816 P. R. China

The Key Laboratory of Bioactive Materials Ministry of Education College of Life Science Nankai University Tianjin 300071 P. R. China

Amgen Bioprocessing Centre Keck Graduate Institute Claremont CA 91711 USA

Funding

National Natural Science Foundation of China · National Key Research and Development Program of China

References (49)

Show source-provided references
1. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
2. 10.1038/s41565-019-0567-y10.1038/s41565-019-0567-y ↗
3. 10.1007/s11426-010-0107-y10.1007/s11426-010-0107-y ↗
4. 10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
5. 10.1016/j.addr.2020.06.00510.1016/j.addr.2020.06.005 ↗
6. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
7. 10.1038/380561a010.1038/380561a0 ↗
8. 10.1016/j.addr.2017.02.00310.1016/j.addr.2017.02.003 ↗
9. 10.1016/j.jconrel.2014.05.03610.1016/j.jconrel.2014.05.036 ↗
10. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
11. 10.1038/nnano.2012.4510.1038/nnano.2012.45 ↗
12. 10.1038/nrclinonc.2010.13910.1038/nrclinonc.2010.139 ↗
13. 10.1038/s41565-020-0759-510.1038/s41565-020-0759-5 ↗
14. 10.1021/acsnano.9b0138310.1021/acsnano.9b01383 ↗
15. 10.1038/nrclinonc.2013.12310.1038/nrclinonc.2013.123 ↗
16. 10.1038/nbt134010.1038/nbt1340 ↗
17. 10.1039/C9CS00575G10.1039/C9CS00575G ↗
18. 10.1016/j.addr.2018.05.00810.1016/j.addr.2018.05.008 ↗
19. 10.1016/j.carbpol.2020.11674910.1016/j.carbpol.2020.116749 ↗
20. 10.1039/D0CS00178C10.1039/D0CS00178C ↗
21. 10.1021/acs.chemrev.8b0040110.1021/acs.chemrev.8b00401 ↗
22. 10.1021/acs.accounts.8b0023310.1021/acs.accounts.8b00233 ↗
23. 10.1016/j.ccr.2013.03.00710.1016/j.ccr.2013.03.007 ↗
24. 10.1038/nphoton.2012.32810.1038/nphoton.2012.328 ↗
25. 10.1038/natrevmats.2017.8010.1038/natrevmats.2017.80 ↗
26. 10.1021/acs.accounts.8b0059110.1021/acs.accounts.8b00591 ↗
27. 10.1039/C7CS00391A10.1039/C7CS00391A ↗
28. 10.1002/adfm.20160598510.1002/adfm.201605985 ↗
29. 10.1016/j.apsb.2020.07.02310.1016/j.apsb.2020.07.023 ↗
30. 10.1038/nrc318010.1038/nrc3180 ↗
31. 10.1038/s41578-020-00269-610.1038/s41578-020-00269-6 ↗
32. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
33. 10.1038/s41568-018-0038-z10.1038/s41568-018-0038-z ↗
34. 10.1038/nrc.2018.1510.1038/nrc.2018.15 ↗
35. 10.1038/s41571-019-0268-310.1038/s41571-019-0268-3 ↗
36. 10.1158/1078-0432.CCR-18-338910.1158/1078-0432.CCR-18-3389 ↗
37. 10.1038/ncomms1445010.1038/ncomms14450 ↗
38. 10.1038/s41467-018-07174-110.1038/s41467-018-07174-1 ↗
39. 10.1021/ja306621n10.1021/ja306621n ↗
40. 10.1007/s13346-020-00820-610.1007/s13346-020-00820-6 ↗
41. 10.1021/acs.bioconjchem.8b0020810.1021/acs.bioconjchem.8b00208 ↗
42. 10.1021/ja411811w10.1021/ja411811w ↗
43. 10.1021/mp400751g10.1021/mp400751g ↗
44. 10.1002/adfm.20200093310.1002/adfm.202000933 ↗
45. 10.1002/adfm.20190643310.1002/adfm.201906433 ↗
46. 10.1016/j.apsb.2020.07.01210.1016/j.apsb.2020.07.012 ↗
47. 10.1002/adfm.20200485110.1002/adfm.202004851 ↗
48. 10.1016/j.carbpol.2020.11749010.1016/j.carbpol.2020.117490 ↗
49. 10.1016/j.apsb.2019.06.00810.1016/j.apsb.2019.06.008 ↗